See more : Chesapeake Energy Corporation (CHKEL) Income Statement Analysis – Financial Results
Complete financial analysis of Propanc Biopharma, Inc. (PPCBD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Propanc Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Calbee, Inc. (2229.T) Income Statement Analysis – Financial Results
- SEL Manufacturing Company Limited (SELMCL.BO) Income Statement Analysis – Financial Results
- Swedbank AB (publ) (SWED-A.ST) Income Statement Analysis – Financial Results
- Minerco, Inc. (MINE) Income Statement Analysis – Financial Results
- TIL Limited (TIL.BO) Income Statement Analysis – Financial Results
Propanc Biopharma, Inc. (PPCBD)
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 256.05K | 230.96K | 179.99K | 260.34K |
| General & Administrative | 1.73M | 1.58M | 3.31M | 2.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.73M | 1.58M | 3.31M | 2.35M |
| Other Expenses | 0.00 | 0.00 | 57.64K | 0.00 |
| Operating Expenses | 1.99M | 1.81M | 3.49M | 2.61M |
| Cost & Expenses | 1.99M | 1.81M | 3.49M | 2.61M |
| Interest Income | 5.61K | 1.00 | 946.00 | 31.00 |
| Interest Expense | 568.80K | 449.46K | 1.75M | 1.31M |
| Depreciation & Amortization | 11.28K | 1.99K | 61.06K | 2.34K |
| EBITDA | -1.98M | -1.81M | -3.43M | -2.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.99M | -1.81M | -3.49M | -2.61M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -722.19K | -327.22K | -1.38M | -3.26M |
| Income Before Tax | -2.71M | -2.14M | -4.88M | -5.87M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -54.98K | -113.42K | -134.73K | -115.44K |
| Net Income | -2.66M | -2.03M | -4.74M | -5.76M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -38.96 | -668.19 | -18.37K | -5.76M |
| EPS Diluted | -38.96 | -668.19 | -18.37K | -5.76M |
| Weighted Avg Shares Out | 68.22K | 3.03K | 258.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 68.22K | 3.03K | 258.00 | 1.00 |
Propanc Biopharma Announces Strategic Pharma Partnering Initiative
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
Source: https://incomestatements.info
Category: Stock Reports